Synapse

← Cancer Drug Resistance

Papers in Cancer Drug Resistance

Page 3 · newest first

  1. Breast cancer cell resistance to hormonal and targeted therapeutics is correlated with the inactivation of the NR6A1 axisCancer Drug Resistance · 2024
  2. Mechanism of ferroptosis resistance in cancer cellsCancer Drug Resistance · 2024
  3. HDAC-driven mechanisms in anticancer resistance: epigenetics and beyondCancer Drug Resistance · 2024
  4. Reprogrammed lipid metabolism in advanced resistant cancers: an upcoming therapeutic opportunityCancer Drug Resistance · 2024
  5. Fra-1 affects chemotherapy sensitivity by inhibiting ferroptosis in gastric cancer cellsCancer Drug Resistance · 2024
  6. The role and clinical applications of exosomes in cancer drug resistanceCancer Drug Resistance · 2024
  7. Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanomaCancer Drug Resistance · 2024
  8. NFE2L2 and ferroptosis resistance in cancer therapyCancer Drug Resistance · 2024
  9. The BET inhibitor sensitivity is associated with the expression level of CDC25B in pancreatic cancer modelsCancer Drug Resistance · 2024
  10. Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer: rationale, challenges, and novel strategiesCancer Drug Resistance · 2024
  11. Emerging roles of small extracellular vesicles in metabolic reprogramming and drug resistance in cancersCancer Drug Resistance · 2024
  12. Competing endogenous RNAs (ceRNAs) and drug resistance to cancer therapyCancer Drug Resistance · 2024
  13. Screening of photosensitizers-ATP binding cassette (ABC) transporter interactions in vitroCancer Drug Resistance · 2024
  14. Intercellular transfer of multidrug resistance mediated by extracellular vesiclesCancer Drug Resistance · 2024
  15. Non-coding RNA and drug resistance in head and neck cancerCancer Drug Resistance · 2024
  16. Current applications of tumor local ablation (TLA) combined with immune checkpoint inhibitors in breast cancer treatmentCancer Drug Resistance · 2024
  17. Cancer-associated fibroblast cell surface markers as potential biomarkers or therapeutic targets in lung cancerCancer Drug Resistance · 2024
  18. Research progress on the role and mechanism of circular RNA in drug resistance of head and neck squamous cell carcinomaCancer Drug Resistance · 2024
  19. The role of circRNAs and miRNAs in drug resistance and targeted therapy responses in breast cancerCancer Drug Resistance · 2024
  20. The uniqueness of ABCB5 as a full transporter ABCB5FL and a half-transporter-like ABCB5βCancer Drug Resistance · 2024
  21. Targeting NETosis: nature’s alarm system in cancer progressionCancer Drug Resistance · 2024
  22. Impact of genetic variants in the solute carrier (SLC) genes encoding drug uptake transporters on the response to anticancer chemotherapyCancer Drug Resistance · 2024
  23. Unraveling the complexity of drug resistance mechanisms to SINE, T cell-engaging therapies and CELMoDs in multiple myeloma: a comprehensive reviewCancer Drug Resistance · 2024
  24. Inhibition of glutaminolysis alone and in combination with HDAC inhibitor has anti-myeloma therapeutic effectsCancer Drug Resistance · 2024
  25. Recent advanced lipid-based nanomedicines for overcoming cancer resistanceCancer Drug Resistance · 2024
  26. The evolving role of immune checkpoint inhibitors in cervical and endometrial cancerCancer Drug Resistance · 2024
  27. Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancerCancer Drug Resistance · 2024
  28. Validation of single nucleotide polymorphisms potentially related to R-CHOP resistance in diffuse large B-cell lymphoma patientsCancer Drug Resistance · 2024
  29. ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategiesCancer Drug Resistance · 2024
  30. Chemosensitizing effect of pentoxifylline in sensitive and multidrug-resistant non-small cell lung cancer cellsCancer Drug Resistance · 2024
  31. Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome themCancer Drug Resistance · 2024
  32. Current knowledge about immunotherapy resistance for melanoma and potential predictive and prognostic biomarkersCancer Drug Resistance · 2024
  33. Isocucurbitacin B inhibits glioma growth through PI3K/AKT pathways and increases glioma sensitivity to TMZ by inhibiting hsa-mir-1286aCancer Drug Resistance · 2024
  34. Emerging role of MYB transcription factors in cancer drug resistanceCancer Drug Resistance · 2024
  35. HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugsCancer Drug Resistance · 2024
  36. The therapeutic potential of circular RNA in triple-negative breast cancerCancer Drug Resistance · 2024
  37. Mechanisms underlying reversed TRAIL sensitivity in acquired bortezomib-resistant non-small cell lung cancer cellsCancer Drug Resistance · 2024
  38. Dysregulation of calcium homeostasis in cancer and its role in chemoresistanceCancer Drug Resistance · 2024
  39. Overcoming immuno-resistance by rescheduling anti-VEGF/cytotoxics/anti-PD-1 combination in lung cancer modelCancer Drug Resistance · 2024
  40. Circular RNA circNCOA3 promotes tumor progression and anti-PD-1 resistance in colorectal cancerCancer Drug Resistance · 2024
  41. Regulation of Nrf2/Keap1 signaling pathway in cancer drug resistance by galectin-1: cellular and molecular implicationsCancer Drug Resistance · 2024
  42. Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptorsCancer Drug Resistance · 2024
  43. Leveraging genomics, transcriptomics and epigenomics to understand chemoimmunotherapy resistance in chronic lymphocytic leukemiaCancer Drug Resistance · 2024
  44. Reactive oxygen species and its role in pathogenesis and resistance to therapy in acute myeloid leukemiaCancer Drug Resistance · 2024
  45. Glycogen synthase kinase 3β: the nexus of chemoresistance, invasive capacity, and cancer stemness in pancreatic cancerCancer Drug Resistance · 2024
  46. Ritonavir reverses resistance to docetaxel and cabazitaxel in prostate cancer cells with acquired resistance to docetaxelCancer Drug Resistance · 2024
  47. Targeting T regulatory (Treg) cells in immunotherapy-resistant cancersCancer Drug Resistance · 2024
  48. Acquisition of drug resistance in endothelial cells by tumor-derived extracellular vesicles and cancer progressionCancer Drug Resistance · 2024
  49. Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinomaCancer Drug Resistance · 2023
  50. Autophagy-related mechanisms for treatment of multiple myelomaCancer Drug Resistance · 2023